CervoMed

CRVO

Specialty Business Services · Industrials

Price

$3.08

-0.06 (-1.91%)

Market Cap

$28.5M

Exchange

NASDAQ Capital Market

Winston Score

–

No score yet — Winston is napping.

We couldn’t gather enough financial data to score this stock reliably.

Share count rising — dilution

+594.5% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 1.3M (2021) → 9.0M (2025)

CervoMed is a small clinical-stage biotech company focused on developing treatments for brain diseases that affect older people. Its main program is neflamapimod, an experimental drug being tested to treat a condition called dementia with Lewy bodies, which causes memory loss and movement problems. The company does not yet sell any products — it is still running clinical trials to prove its drug is safe and effective.

CervoMed makes no revenue from product sales right now. It funds its operations through cash raised from investors, which is common for early-stage drug developers. The company is based in the United States and is very small, with a market cap near zero, meaning it carries significant financial risk. The biggest factor that will determine its future is whether neflamapimod succeeds in clinical trials — a positive result could open a large market with few approved treatments, but a failed trial would put the company's survival in serious doubt.

Winston Score History

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

Revenue data limited

EPS Growth

-53.6% YoY

YoY Growth Rate

Earnings declining

R&D Spend

$22M/ year

↑ Rising (+16% vs prior year)

R&D investment increasing — building for the future

Insider Activity

39.4%ownership

Insiders own a meaningful stake in the company

Cash Runway

~5 months

$13M cash & investments

Quarterly Free Cash Flow

↓ Burn rate worsening

Short runway — potential dilution ahead through share issuance

Cash watch

CervoMed has less than a year of cash at its current burn rate. Growth investors should watch for potential share dilution from future fundraising — that directly reduces your ownership.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin

N/A

Data not available

Operating Margin

N/A

Data not available

ROCE

-76.4%

Weak — -76.4% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY

N/A

—

Data not available

EPS YoY

N/A

Data not available

EPS Consistency

0/8 quarters

Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion

N/A

—

Data not available

FCF Margin

-8548.2%

Burning cash (-8548.2%)

Free cash flow is negative. They are burning cash, not generating it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity

N/A

Data not available

Interest Cover

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)

N/M

—

Negative earnings — P/E not meaningful

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial